Research programme: specifically-targeted antimicrobial peptides - C3J Thera peutics

Drug Profile

Research programme: specifically-targeted antimicrobial peptides - C3J Thera peutics

Alternative Names: C3CD-17; MRSA STAMP; Sm STAMP

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator C3 Jian
  • Developer C3J Therapeutics
  • Class Peptide fragments
  • Mechanism of Action Peptide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Clostridium infections; Dental caries; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections

Most Recent Events

  • 29 Nov 2016 C3 Jian is now called C3J Therapeutics
  • 17 Mar 2014 Preclinical development is ongoing in the US
  • 01 Jan 2007 Preclinical trials in Bacterial infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top